psoriasis, Psoriasis Treatments

8 Weeks with Tremfya: It’s Working!

On Monday I hit the eight-week mark on Tremfya (guselkumab), Janssen’s new biologic indicated for plaque psoriasis. Over the weekend, it felt like the remaining psoriasis started melting away as lesions flattened, looked less red, and even disappeared. But with a change in medical providers I'm still unsure if insurance will continue to cover the cost of Tremfya.

Local News, Personal Faith

Call to Prayer: Northern California Wildfires

The Northern California wildfires made their presence known in our neighborhood earlier this week as fine ash blanketed the city. I ran to my car, amazed a few minutes later how my asthma flared so quickly. Psalm 46 is a psalm I'm praying for Northern California. May God be the refuge and strength of all those who are fearful, anxious, or experiencing loss.

psoriasis, Psoriasis Treatments

6 Weeks with Tremfya: Redefining Expectations

When I started taking Tremfya (guselkumab), I carried an unstated goal and expectation: clear skin. I looked at the graphs and incredible data on the effectiveness of Tremfya and just figured I could enjoy life with less and less psoriasis over the course of sixteen weeks. At six weeks, some forty-two days later, I’m readjusting my expectations.

psoriasis, Psoriasis Treatments

5 Weeks with Tremfya: Biggest Fear?

I’m a dreamer. Psoriasis treatments, however, dash my hopes more times I care to remember. After five weeks on the new biologic medication Tremfya (guselkumab) do I dare to dream that it just might clear my skin of nasty psoriasis lesions? What is my biggest fear taking a new biologic for the first time in years?

psoriasis, Psoriasis Treatments

The Waiting is the Hardest Part: A Reflection on Psoriasis Treatments

Five years ago I wrote about the challenges of waiting for a new treatment, Stelara, to work after taking it for three weeks. It never did, even after six months. I find myself at a similar juncture today--a few weeks into Tremfya treatment wondering the same.